The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study on the anticancer effects of novel candidate agent COH-SR4 in lung cancer.